Related Experiment Video
Updated: May 20, 2026
Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
Published on: November 5, 2014
Targeting claudin-4 in human pancreatic cancer
Takashi Kojima1, Daisuke Kyuno, Norimasa Sawada
1Sapporo Medical University School of Medicine, Department of Pathology, Sapporo, Japan. ktakashi@sapmed.ac.jp
Introduction:
Pancreatic cancer is one of the most malignant human diseases and there is an urgent need to develop novel diagnostic and therapeutic strategies. Claudin-4, overexpressed in pancreatic cancer and its precursor lesions, is a receptor for Clostridium perfringens enterotoxin (CPE). The cytotoxic effects of CPE and monoclonal antibodies against claudin-4 are useful as novel therapeutic tools for pancreatic cancer.
Areas Covered:
This review describes and discusses the studies targeting claudin-4 in normal human pancreatic duct epithelial (HPDE) cells and cancer cells.
Expert Opinion:
Claudin-4 is in part regulated via a PKCα signal transduction pathway in pancreatic cancer cell lines. PKCα inhibitors may represent potential therapeutic agents against human pancreatic cancer cells by the use of CPE cytotoxicity via claudin-4. The COOH-terminal half fragment of CPE (C-CPE) enhances the effectiveness of clinically relevant chemotherapies and can be used as a carrier for drugs and other bacterial toxins to claudin-4-positive cancer cells. hTERT-HPDE cells, in which the human telomerase reverse transcriptase (hTERT) gene is introduced into normal HPDE cells, may be a useful model of normal HPDE cells not only for physiological regulation of claudin-4 expression but also for developing safer and more effective therapeutic methods targeting claudin-4 in pancreatic cancer.
Insights
Targeting claudin-4, a protein overexpressed in pancreatic cancer, shows therapeutic promise. Clostridium perfringens enterotoxin (CPE) and its derivatives offer novel strategies for pancreatic cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Pancreatic cancer is a highly lethal disease requiring new therapeutic and diagnostic approaches.
- Claudin-4 is significantly overexpressed in pancreatic cancer and its precursor lesions.
- Claudin-4 serves as a receptor for Clostridium perfringens enterotoxin (CPE).
Purpose of the Study:
- To review and discuss studies investigating claudin-4 targeting in normal and cancerous pancreatic cells.
- To explore the therapeutic potential of targeting claudin-4 in pancreatic cancer.
Main Methods:
- Review of existing literature on claudin-4 targeting strategies.
- Analysis of claudin-4 regulation via signal transduction pathways.
- Evaluation of Clostridium perfringens enterotoxin (CPE) and its derivatives as therapeutic agents.
Main Results:
- Claudin-4 expression is partially regulated by the PKCα signaling pathway in pancreatic cancer cells.
- PKCα inhibitors may enhance CPE-mediated cytotoxicity against pancreatic cancer cells.
- The C-CPE fragment can potentiate chemotherapy and act as a drug delivery vehicle.
Conclusions:
- Targeting claudin-4 with CPE or its derivatives presents a promising therapeutic avenue for pancreatic cancer.
- PKCα inhibitors offer a potential strategy to enhance CPE-based therapies.
- Engineered cell lines like hTERT-HPDE provide valuable models for studying claudin-4 regulation and developing targeted therapies.
